olipass与Squibb达成了PNA基化合物治疗策略的战略联盟

     olipass生物制药公司是一家致力于开发基于反义药物的肽核酸（PNA）技术的生物公司。olipass昨日与布里斯托尔梅尔斯Squibb公司在开发治疗使用olipass技术平台的多个目标达成全球战略联盟。根据协议的条款，公司将做一个预先付款，将提供一定的研究支持支付不断的技术开发。在一定目标的完成之后olipass将有资格获得额外的付款。

  此外，olipass将有资格在每个产品的销售许可的BMS根据协议以及基于层次的授权产品销售其他里程碑获得发展的里程碑和版税。“我们是一个主要的跨国制药公司，宣布我们的第一次合作我们很兴奋。”olipass的创始人和首席执行官新中博士说。“这一战略联盟与布里斯托尔梅尔斯Squibb表明我们创新的PNA平台具有产生新的反义治疗潜力。我们期待与布里斯托尔梅尔斯Squibb公司合作来验证我们的平台，推进我们独特的PNA基化合物的发展。”

  olipass公司在韩国水原成立于2006，是一家私人持有的生物制药公司，以提供解决方案的关键技术障碍对寡核苷酸的药物的发展。olipass合理设计的肽核酸具有细胞渗透性好，已经证明在体内的反义治疗活动以前所未有的小剂量不依赖复杂的公式。

原文：

OliPass Announces a Worldwide Discovery Alliance with Bristol-Myers Squibb for PNA-based Therapeutics

SUWON, South Korea, October 28, 2014 /PRNewswire/ -- OliPass, a privately held biopharmaceutical company focused on developing antisense medicines based on peptide nucleic acid (PNA) technology, today announced a worldwide strategic alliance with Bristol-Myers Squibb Company to discover and develop therapeutics against multiple targets using OliPass' technology platform.

Under the terms of the agreement, BMS will make an up-front payment and will provide certain research support payments to continue development of the technology. OliPass will be eligible to receive additional payments upon completion of certain objectives.

In addition, OliPass will be eligible to receive development milestones and royalties on the sales of each product licensed to BMS under the Agreement as well as other milestones based on the level of licensed product sales.

"We are thrilled to announce our first collaboration with a major multi-national pharmaceutical company," said Dr.Shin Chung, founder and chief executive officer of OliPass. "This strategic alliance with Bristol-Myers Squibb demonstrates that our innovative PNA platform has the potential to generate novel antisense therapeutics. We look forward to collaborating with Bristol-Myers Squibb to validate our platform and advance our unique PNA-based compounds into development."

OliPass Corporation is a privately held biopharmaceutical company in Suwon, Republic of Korea, founded in 2006 in order to provide solutions to key technical hurdles against the development of oligonucleotide drugs. OliPass rationally designed peptide nucleic acids possessing good cell permeability and have demonstrated in vivo antisense therapeutic activity at an unprecedentedly small dose without relying on complex formulation.

（转化医学网360zhyx.com）